Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025

Prime Medicine, Inc.

2024-FY EPS reported -$1.65 revenue$2,983,000

Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.
Cash, equivalents, and investments $204.5M at Dec 31, 2024, up from $135.2M.
Initial clinical data from PM359 Phase 1/2 for p47 phox CGD expected in 2025.
IND/CTA filing for PM577 (Wilson's Disease) planned for first half of 2026.
Cash runway expected into first half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.